Abstract 2058P
Background
Strategies targeting oral anticancer drug (OAD) waste are required to improve sustainability and affordability of these expensive treatments frequently remaining unused by patients. This study aims to quantify waste reduction, cost-savings and environmental impact obtained by redispensing unused OADs compared to standard practice of disposal.
Methods
A prospective, single-arm intervention study was conducted in four Dutch hospitals. Eligible patients were ≥18 years, diagnosed with cancer and prescribed an OAD. During twelve months, participants received OAD packages sealed with a time-temperature indicator. If unused, OADs were returned to the pharmacy where quality was assured by checking authenticity, shelf life and storage temperature. OADs of verified quality were redispensed to other patients. Waste reduction was expressed as the percentage returned OADs that were redispensed. Mean annual cost-savings per patient were costs of redispensed OADs minus operational expenses from a healthcare perspective. Impact on environmental indicators was assessed via a cradle-to-grave Life Cycle Assessment. Patient subgroups associated with positive cost-savings were identified with multiple logistic regression. Scenarios analyses on the effect of optimized quality assurance and patient population selection was performed.
Results
1,071 patients participated, median age 70 years (IQR: 62–75) and 41.9% female. 224 OAD packages (1.7%) of 128 patients (12.0%) were redispensed (2.4% of total drug costs), reducing waste by 68.1% and providing mean annual cost-savings of €576 per patient (95% CI: 444–709). Optimizing quality assurance and targeting patient subgroups (< 24 months OAD use/using targeted therapies) could increase mean annual cost-savings up to €1,348 (1,039 – 1,697) per patient. Waste reduction was associated with mean annual environmental benefits of >1 kg CO2 per patient, but only with an optimized quality assurance procedure a net beneficial impact on environmental indicators was achieved.
Conclusions
Redispensing unused OADs reduces waste substantially, generates cost-savings and can benefit environmental impact, improving sustainability and affordability of cancer treatment.
Clinical trial identification
WHO International Clinical Trials Registry Platform (ICTRP) Identifier: NL9208.
Editorial acknowledgement
Legal entity responsible for the study
ROAD-study group.
Funding
Netherlands Organisation for Health Research and Development ZonMw (grant 848018008).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06